nct_id: NCT06097728
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-10-24'
study_start_date: '2023-11-09'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Nivolumab'
  - drug_name: 'Drug: Cisplatin'
  - drug_name: 'Drug: Carboplatin'
  - drug_name: 'Drug: Volrustomig'
  - drug_name: 'Drug: Pemetrexed'
  - drug_name: 'Drug: Ipilimumab'
long_title: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig
  (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus
  Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural
  Mesothelioma (eVOLVE-Meso)
last_updated: '2025-11-14'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: Marjorie G Zauderer, MD
principal_investigator_institution: Memorial Slone Kettering (MSK) Cancer Centre
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 825
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- "* Participant must be \u2265 18 years at the time of screening"
- '* Histologically proven diagnosis of pleural mesothelioma with known histology
  (epithelioid vs. non-epithelioid)'
- '* Advanced unresectable disease that cannot be treated with curative surgery (with
  or without chemotherapy)'
- '* WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS\>1)
  over the previous 2 weeks prior to day of first dosing'
- '* Has measurable disease per modified RECIST1.1'
- '* Has adequate bone marrow reserve and organ function at baseline'
- 'Exclude - Key Exclusion Criteria:'
- Exclude - * As judged by the investigator, any condition that would interfere with
  evaluation of the investigational product or interpretation of participant safety
  or study results.
- Exclude - * Active or prior documented autoimmune or inflammatory disorders
- Exclude - * History of another primary malignancy with exceptions.
- Exclude - * Uncontrolled intercurrent illness
- Exclude - * Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency
  virus (HIV) infection that is not well controlled
- Exclude - * Any concurrent chemotherapy, radiotherapy, investigational, biologic,
  or hormonal therapy for cancer treatment
- Exclude - * Untreated or progressive CNS metastatic disease
short_title: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable
  Pleural Mesothelioma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a phase III, randomized, open-label, multicenter, global study to
  determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed
  vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab
  in participants with unresectable pleural mesothelioma.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Volrustomig + Carboplatin + pemetrexed
      arm_internal_id: 0
      arm_description: Volrustomig in combination with carboplatin plus pemetrexed
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Volrustomig'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Investigator's choice of standard care
      arm_internal_id: 1
      arm_description: The investigator's choice of nivolumab plus ipilimumab or platinum
        plus pemetrexed chemotherapy for participants with epithelioid histology,
        and nivolumab plus ipilumab for participants with non-epithelioid histology.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pemetrexed'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Carboplatin'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Cisplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Nivolumab'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Ipilimumab'
        level_internal_id: 4
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Advanced
        - Unresectable
        - Untreated
        oncotree_primary_diagnosis: Pleural Mesothelioma
